share_log

DaVita | 8-K: Current report

DaVita | 8-K: Current report

德维特 | 8-K:重大事件
美股SEC公告 ·  2024/10/30 04:17

Moomoo AI 已提取核心信息

DaVita delivered solid Q3 2024 financial results with consolidated revenues of $3.26B and operating income of $535M, representing a 16.4% operating margin. Diluted earnings per share reached $2.50, while adjusted EPS was $2.59. Operating cash flow strengthened to $810M with free cash flow of $555M.The company completed significant debt refinancing in August, securing a $1.1B Term Loan A-1 tranche and issuing $1.0B in 6.875% senior notes. The proceeds were used to repay approximately $950M Term Loan B-1 maturing in 2026 and outstanding revolving credit. During Q3, DaVita repurchased 2.7M shares at an average price of $147.20 per share.U.S. dialysis metrics showed stable performance with 7.35M total treatments in Q3, averaging 93,048 treatments per day. Revenue per treatment increased to $394.49, up from $390.22 in Q2. The company maintained its 2024 guidance with adjusted operating income projected between $1.91B-$2.01B and adjusted EPS forecast of $9.25-$10.05.
DaVita delivered solid Q3 2024 financial results with consolidated revenues of $3.26B and operating income of $535M, representing a 16.4% operating margin. Diluted earnings per share reached $2.50, while adjusted EPS was $2.59. Operating cash flow strengthened to $810M with free cash flow of $555M.The company completed significant debt refinancing in August, securing a $1.1B Term Loan A-1 tranche and issuing $1.0B in 6.875% senior notes. The proceeds were used to repay approximately $950M Term Loan B-1 maturing in 2026 and outstanding revolving credit. During Q3, DaVita repurchased 2.7M shares at an average price of $147.20 per share.U.S. dialysis metrics showed stable performance with 7.35M total treatments in Q3, averaging 93,048 treatments per day. Revenue per treatment increased to $394.49, up from $390.22 in Q2. The company maintained its 2024 guidance with adjusted operating income projected between $1.91B-$2.01B and adjusted EPS forecast of $9.25-$10.05.
德维特发布了2024年第三季度强劲的财务业绩,合并营业收入为32.6亿,营业收入为53500万,营业利润率为16.4%。稀释每股收益达到2.50美元,而调整后每股收益为2.59美元。营业现金流增强至81000万,自由现金流为55500万。公司在八月完成了重要的债务再融资,获得了11亿的A-1期贷款,并发行了10亿的6.875%高级票据。所得款项用于偿还大约95000万在2026年到期的B-1期贷款和未偿还的循环信贷。在第三季度,德维特回购了270万股,平均回购价格为每股147.20美元。美国透析指标显示出稳定的表现,第三季度总治疗次数为735万,平均每天93,048次治疗。每次治疗的营业收入增长至394.49美元,较第二季度的390.22美元有所上升。公司维持2024年的指导,预计调整后的营业收入在19.1亿至20.1亿之间,调整后的每股收益预测为9.25至10.05美元。
德维特发布了2024年第三季度强劲的财务业绩,合并营业收入为32.6亿,营业收入为53500万,营业利润率为16.4%。稀释每股收益达到2.50美元,而调整后每股收益为2.59美元。营业现金流增强至81000万,自由现金流为55500万。公司在八月完成了重要的债务再融资,获得了11亿的A-1期贷款,并发行了10亿的6.875%高级票据。所得款项用于偿还大约95000万在2026年到期的B-1期贷款和未偿还的循环信贷。在第三季度,德维特回购了270万股,平均回购价格为每股147.20美元。美国透析指标显示出稳定的表现,第三季度总治疗次数为735万,平均每天93,048次治疗。每次治疗的营业收入增长至394.49美元,较第二季度的390.22美元有所上升。公司维持2024年的指导,预计调整后的营业收入在19.1亿至20.1亿之间,调整后的每股收益预测为9.25至10.05美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息